Icahn responds to claims he's trying to sell Amylin to Lilly
Billionaire investor Carl Icahn has responded to claims by Amylin's board that he is pushing to sell the company to Eli Lilly (see page 4) as he did ImClone last year (Marketletters passim). Mr Icahn criticized the US biotechnology firm's chairman, Joseph Cook, and independent director, James Wilson, for misrepresenting his views and resisting his management suggestions. The industrialist claimed in an open letter that he was not looking for an immediate sale of Amylin, but merely thought investors should have the chance to judge any offers for the company themselves. He adds that he will only advise a sale if an offer exceeded $30 per share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze